Lv3
280 积分 2024-06-03 加入
Interleukin-6: from an inflammatory marker to a target for inflammatory diseases
2天前
已完结
Rethinking IL-6 and CRP: Why they are more than inflammatory biomarkers, and why it matters
2天前
已完结
C-Reactive Protein, Interleukin 6, and Risk of Developing Type 2 Diabetes Mellitus
2天前
已完结
The FGF family: biology, pathophysiology and therapy
4天前
已完结
Association of d-dimer levels with in-hospital outcomes among COVID-19 positive patients: a developing country multicenter retrospective cohort
5天前
已完结
Immunogenicity and safety of concomitant bivalent COVID-19 and quadrivalent influenza vaccination: implications of immune imprinting and interference
11天前
已完结
Mutation N856K in spike reduces fusogenicity and infectivity of Omicron BA.1
18天前
已完结
A multi-center, open-label, randomized, parallel-controlled phase II study comparing pharmacokinetic, pharmacodynamics and safety of ripertamab (SCT400) to rituximab (MabThera� in patients with CD20-positive B-cell non-Hodgkin lymphoma
19天前
已完结
A Randomized, Double-Blind, Parallel-Controlled Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of SCT510 to Bevacizumab (Avastin®) in Healthy Chinese Males
19天前
已完结
Efficacy, safety and pharmacokinetics of recombinant human coagulation factor VIII (omfiloctocog alfa) in previously treated Chinese children with severe hemophilia A
19天前
已完结
皖公网安备34019202002308
